CTLA4 and hepatocellular carcinoma: Over the past few years, great progress was made in the application of immune checkpoint inhibitors (ICI) such as cytotoxic T lymphocyte antigen 4 (CTLA-4), PD-1, and PD-L1 for the clinical treatment of HCC (Sprinzl and Galle, 2017).